Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Mednax, Inc. (NYSE: MD) resulting from allegations that Mednax may have issued materially misleading business information to the investing public.

On July 28, 2017, Mednax announced during its second quarter earnings call that it had not completed acquisitions of anesthesiologist practices during the quarter and that any future anesthesiologist acquisitions were unlikely. On this news, Mednax’s stock price fell $8.76 per share or 15.5% to close at $47.73 per share on July 28, 2017.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Mednax investors. If you purchased shares of Mednax please visit the firm’s website at http://www.rosenlegal.com/cases-1378.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or zhalper@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.

Attorney Advertising. Prior results do not guarantee a similar outcome.